PRGS-1 is under clinical development by PRG S&Tech and currently in Phase I for Werner Syndrome. According to GlobalData, Phase I drugs for Werner Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PRGS-1 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRGS-1 (progerinin) is under development for the treatment of Hutchinson-Gilford progeria and Werner syndrome. It is administered through oral route.
PRG S&Tech overview
PRG S&Tech specializes in the research and development of medicine for genopathies diseases. PRG S&Tech is headquartered in Busan,South Korea.
For a complete picture of PRGS-1’s drug-specific PTSR and LoA scores, buy the report here.